Pityriasis lichenoides chronica induced by COVID-19 messenger RNA vaccination

Muqrin, Abdullah Al; Alruwaili, Ziyad Muharib N

doi:10.1016/j.jdcr.2022.07.017

Cited by 4 publications

(5 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 43 A course of doxycycline was attempted in the case of the patient with a PLC eruption by Al Muqrin et al , however the final outcome of the treatment was not reported. 29 In the other two PLC patients reported in this systematic review, symptoms resolved either through the use of doxycycline or on their own, leaving hyperpigmented macules. 34 , 35 …”

Section: Resultsmentioning

confidence: 83%

“… 22 , 33 15 (16.0%) reactions resulted in PRP, 10-13 ,15- 18,24,36,45,46 and 7 (7.4%) were diagnosed as PLEVA,12,14,19,37,40,43,50 and 3 (3.2%) were diagnosed as PLC. 29 , 34 , 35 5 (5.3%) were described as “atypical”. 41 51 of the 97 cases reported the existence of herald patches in a variety of locations including the arm, wrist, breast, axilla, back, abdomen, and thigh.20,22,27,28,30-33,38,39,41,42,47-49,52- 56 Only one case reported a herald patch occurring at the inoculation site.…”

Section: Resultsmentioning

confidence: 99%

“…Treatments of PR and PR-like reactions were a combination of the following: topical and oral corticosteroid(s) including prednisolone, mometasone, betamethasone, 21 , 22 ,26,28,33,38,41,44,50, 52 standard triamcinolone 0.1% ointment, 20 , 23 , 31 , 42 , 55 doxycycline, 22 , 29 , 34 oral acyclovir, 30 ganciclovir, 51 valaciclovir, 51 antihistamines, 21 , 28 , 33 , 41 emollients, 53 and L-lysine. 27 Pityriasis rosea was reported to have resolved on its own in two cases.…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Pityriasis following COVID-19 vaccinations: a systematic review

Duzett,

Mercado,

Tasouli-Drakou

et al. 2023

Dermatol Reports

View full text Add to dashboard Cite

In the wake of a global COVID-19 pandemic, where innovations in vaccination technology and the speed of development and distribution have been unprecedented, a wide variety of post-vaccination cutaneous reactions have surfaced. However, there has not been a systematic review that investigates pityriasis eruptions and the associated variants following COVID-19 inoculations. A PubMed search using Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) was performed to find case reports from the earliest record through November 2022. Data including types of vaccination and pityriasis were extracted and a quality review was performed. 47 reports with 94 patients were found: 64.9% had pityriasis rosea (PR), 3.2% PR-like eruptions, 16.0% pityriasis rubra pilaris (PRP), 7.4% pityriasis lichenoides et varioliformis acuta (PLEVA), 3.2% pityriasis lichenoides chronica (PLC), and 5.3% had reactions described as “atypical”. The top three COVID-19 vaccinations reported were Pfizer-BioNTech (47.9%), Oxford-AstraZeneca (11.7%), and Moderna (8.5%). Pityriasis reactivity was reported most frequently after the Pfizer-BioNTech vaccination, with pityriasis rosea being the most common variant. A large difference was additionally found between the ratio of post-vaccination pityriasis reactions following Pfizer and Moderna vaccinations (5.63), and the ratio of Pfizer’s usage in the United States as of December 28, 2022 relative to that of Moderna (1.59). Further studies with adequate follow-up periods and diagnostic testing will thus need to be performed to elucidate the root of this discrepancy and better characterize the association between different pityriasis reactions and COVID-19 vaccinations.

show abstract

Section: Resultsmentioning

confidence: 83%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Pityriasis following COVID-19 vaccinations: a systematic review

Duzett,

Mercado,

Tasouli-Drakou

et al. 2023

Dermatol Reports

View full text Add to dashboard Cite

show abstract

“…Thirteen articles, comprising 14 cases of PL following SARS-CoV-2 infection/vaccination, were included [ 6 – 15 , 16 •, 17 , 18 •]. The mean age of those affected was 41.4 years (median 41.0 years, range 6.0–81.0 years) and 64.3% of those affected were male.…”

Section: Resultsmentioning

confidence: 99%

“…Thirteen articles, comprising 14 cases of PL following SARS-CoV-2 infection/vaccination, were included [6][7][8][9][10][11][12][13][14][15]16 Studies excluded during title/abstract screen (n = 10)…”

Section: Resultsmentioning

confidence: 99%

Pityriasis Lichenoides Following SARS-CoV-2 Infection/Vaccination

et al. 2023

View full text Add to dashboard Cite

Purpose of Review Pityriasis lichenoides (PL) is a spectrum of dermatological conditions involving polymorphous lesions. Natural history of the condition ranges from acute to chronic. Cases of PL following SARS-CoV-2 infection/vaccination have been reported, but not yet comprehensively reviewed. Hence, the objective of this article is to review and summarize cases of PL following SARS-CoV-2 infection/vaccination in order to guide clinicians in its diagnosis and management. Recent Findings PubMed, Embase, and Web of Science were searched for relevant articles. Thirteen articles, consisting of 14 cases of PL following SARS-CoV-2 infection/vaccination, were identified. Males represented 64.3% of cases, and the average age of those affected was 41.4 years. The majority of cases ( N = 9, 64.3%) were following SARS-CoV-2 vaccination, the most commonly implicated being Pfizer-BioNTech ( n = 8/10, 80%), while four (28.6) followed infection. The overall latency period ranged from 5 days to 1 month. Treatments varied greatly. However, at the time of follow-up, 12/14 patients (85.7%) had either marked improvement or complete resolution of lesions. Summary This review cannot determine causality. However, a temporal association was observed with the case reports, and one case of PL followed SARS-CoV-2 infection and recurred with subsequent vaccination, suggesting an association. Nevertheless, risk of developing PL following SARS-CoV-2 infection/vaccination is likely extremely low. There is also the possibility these cases are purely coincidental. Still, clinicians should be aware of this possible etiology when diagnosing a new or exacerbated case of PL. Finally, given that the majority of patients had marked improvement or complete resolution of lesions at the time of follow-up, clinicians should provide reassurance to their affected patients.

show abstract

Pityriasis lichenoides acuta after COVID-19 vaccination

Singh

2024

Preprint

View full text Add to dashboard Cite

This case is notable due to the possible association between pityriasis lichenoides et varioliformis acuta (PLEVA) and the COVID-19 vaccination. In this case report we discuss a case of a 32 year-old male who developed erythematous, oval-shaped papules on his trunk, upper and lower extremities 2 weeks after his Covid 19 vaccination. We also discussing the the diagnostic and therapeutic challenge of this disease and how a misdiagnosis of this disease can lead to great amount of emotional and psychological stress for the patient and his family members. For this reason it is important to have this on the list of possible diagnosises.

show abstract

Pityriasis lichenoides chronica induced by COVID-19 messenger RNA vaccination

Cited by 4 publications

References 15 publications

Pityriasis following COVID-19 vaccinations: a systematic review

Pityriasis following COVID-19 vaccinations: a systematic review

Pityriasis Lichenoides Following SARS-CoV-2 Infection/Vaccination

Pityriasis lichenoides acuta after COVID-19 vaccination

Contact Info

Product

Resources

About